KOMET-017

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Feb 11, 2025 → Oct 14, 2026

Cited window

Feb 11, 2025 → Oct 14, 2026

Retrieved

Oct 18, 2026

Title

Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia

Registry

NCT07007312

Study IDs

KO-MEN-017 · 2025-521314-25-00

Sponsor

Kura Oncology, Inc.

Design

Phase 3 · Interventional, randomized, parallel

Status

Recruiting

Enrollment

1,300 estimated

Start

2025-09-26 actual

Primary completion

2031-11 estimated

Primary endpoint

Nonintensive Therapy Study: (Primary Endpoint for all countries): Overall survival (OS)

Interventions

6 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –16 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The discussion comes from the sources reviewed for this edition and cannot establish how common these views are among HCPs. Several posts report presentations rather than independent clinical assessments.
• –No protocol or results publication for the exact KOMET-017 trial was identified. The clinical observations discussed here must not be treated as randomized KOMET-017 findings.
• –The earlier response and safety accounts often omit denominators, follow-up duration or numerical rates. A speaker's 40-patient response figures cannot be assigned to a specific frontline or relapsed/refractory cohort from the passage.
• –Speaker descriptions differ in regimen detail: a speaker named azacitidine/venetoclax, whereas another speaker's older/unfit KOMET-017 comparison named azacitidine without venetoclax. These descriptions do not establish a clinical disagreement.
• –The differentiation-syndrome comparisons concern different inhibitors, schedules and treatment settings. They do not establish a head-to-head safety advantage or a causal effect of starting treatment later.

How reports are built and checked: Methods.

Last checked for new commentary Oct 19, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "KOMET-017" (NCT07007312), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "komet-017-07007312". If you cannot make requests, read https://www.erudio.com/reports/komet-017-nct07007312.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT07007312", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct07007312 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/komet-017-nct07007312.json
curl https://www.erudio.com/reports/komet-017-nct07007312.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "komet-017-07007312" })